Nanoemulsion as a feasible and biocompatible carrier for ocular delivery of travoprost: Improved pharmacokinetic/pharmacodynamic properties

[Display omitted] Travoprost is a synthetic prostaglandin F2α analogue used in treatment of glaucoma. Due to its water insolubility and oily nature, novel delivery systems need to be developed to enhance its bioavailability, and sustain its release. In the current work, travoprost nanoemulsion was e...

Full description

Saved in:
Bibliographic Details
Published in:International journal of pharmaceutics 2020-06, Vol.583, p.119402, Article 119402
Main Authors: Ismail, Ayman, Nasr, Maha, Sammour, Omaima
Format: Article
Language:English
Subjects:
Administration, Ophthalmic
Animals
Antihypertensive Agents - administration & dosage
Antihypertensive Agents - pharmacokinetics
Antihypertensive Agents - toxicity
Biological Availability
Drug Carriers
Drug Compounding
Emulsions
Feasibility Studies
Glaucoma
Glaucoma - drug therapy
Glaucoma - physiopathology
Intraocular Pressure - drug effects
Lipids - chemistry
Nanoemulsion
Nanoparticles
Ocular Absorption
Ophthalmic Solutions
Pharmacokinetics
Rabbits
Stability
Travoprost
Travoprost - administration & dosage
Travoprost - pharmacokinetics
Travoprost - toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:[Display omitted] Travoprost is a synthetic prostaglandin F2α analogue used in treatment of glaucoma. Due to its water insolubility and oily nature, novel delivery systems need to be developed to enhance its bioavailability, and sustain its release. In the current work, travoprost nanoemulsion was explored as a novel carrier prepared using low energy technique. Results showed that travoprost nanoemulsions exhibited suitable nanodroplet size, zeta potential, pH, refractive index, controlled release, as well as sufficient stability under accelerated conditions. In vivo studies delineated the enhanced absorption of travoprost nanoemulsion compared to the marketed eye drops Travatan®, as proven by the higher Cmax and AUC of the former, and its prolonged intraocular pressure reduction time. Moreover, the nanoemulsion formulation was proven safe and non-irritant to ocular surfaces. Therefore, it can be suggested that travoprost nanoemulsion is a promising ocular delivery system for glaucoma treatment.
ISSN:0378-5173
1873-3476
DOI:10.1016/j.ijpharm.2020.119402